$TKNO
Alpha Teknova, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022009650 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $11.15M $9.078M
YoY Change 22.79% 48.53%
Cost Of Revenue $5.798M $4.053M
YoY Change 43.05% 63.23%
Gross Profit $5.349M $5.025M
YoY Change 6.45% 38.47%
Gross Profit Margin 47.99% 55.35%
Selling, General & Admin $8.892M $4.866M
YoY Change 82.74% 142.81%
% of Gross Profit 166.24% 96.84%
Research & Development $2.013M $700.0K
YoY Change 187.57% 114.72%
% of Gross Profit 37.63% 13.93%
Depreciation & Amortization $751.0K $652.0K
YoY Change 15.18% 43.93%
% of Gross Profit 14.04% 12.98%
Operating Expenses $11.19M $5.853M
YoY Change 91.22% 123.65%
Operating Profit -$5.843M -$828.0K
YoY Change 605.68% -181.82%
Interest Expense -$13.00K $7.000K
YoY Change -285.71% -78.13%
% of Operating Profit
Other Income/Expense, Net -$13.00K $8.000K
YoY Change -262.5% -138.1%
Pretax Income -$5.856M -$820.0K
YoY Change 614.15% -180.16%
Income Tax -$400.0K -$200.0K
% Of Pretax Income
Net Earnings -$5.497M -$655.0K
YoY Change 739.24% -169.09%
Net Earnings / Revenue -49.31% -7.22%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$196.1K -$24.16K
COMMON SHARES
Basic Shares Outstanding 28.04M
Diluted Shares Outstanding 28.03M 3.599M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.46M $14.47M
YoY Change 428.52%
Cash & Equivalents $76.46M $14.47M
Short-Term Investments $0.00
Other Short-Term Assets $1.891M $2.247M
YoY Change -15.84%
Inventory $6.426M $3.879M
Prepaid Expenses
Receivables $5.978M $4.197M
Other Receivables $1.188M $1.594M
Total Short-Term Assets $91.94M $26.38M
YoY Change 248.47%
LONG-TERM ASSETS
Property, Plant & Equipment $37.06M $13.53M
YoY Change 173.98%
Goodwill $16.61M
YoY Change
Intangibles $18.42M
YoY Change
Long-Term Investments
YoY Change
Other Assets $396.0K $33.00K
YoY Change 1100.0%
Total Long-Term Assets $92.15M $49.74M
YoY Change 85.27%
TOTAL ASSETS
Total Short-Term Assets $91.94M $26.38M
Total Long-Term Assets $92.15M $49.74M
Total Assets $184.1M $76.12M
YoY Change 141.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.028M $2.918M
YoY Change 3.77%
Accrued Expenses $7.510M $3.174M
YoY Change 136.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.64M $6.092M
YoY Change 107.42%
LONG-TERM LIABILITIES
Long-Term Debt $11.92M $11.74M
YoY Change 1.53%
Other Long-Term Liabilities $18.19M $541.0K
YoY Change 3262.48%
Total Long-Term Liabilities $30.11M $12.28M
YoY Change 145.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.64M $6.092M
Total Long-Term Liabilities $30.11M $12.28M
Total Liabilities $45.54M $24.19M
YoY Change 88.21%
SHAREHOLDERS EQUITY
Retained Earnings -$13.04M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $138.5M $16.29M
YoY Change
Total Liabilities & Shareholders Equity $184.1M $76.12M
YoY Change 141.83%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$5.497M -$655.0K
YoY Change 739.24% -169.09%
Depreciation, Depletion And Amortization $751.0K $652.0K
YoY Change 15.18% 43.93%
Cash From Operating Activities -$5.201M $2.401M
YoY Change -316.62% -3028.05%
INVESTING ACTIVITIES
Capital Expenditures $5.917M $3.884M
YoY Change 52.34% -1181.89%
Acquisitions
YoY Change
Other Investing Activities $0.00 $2.356M
YoY Change -100.0% 35.17%
Cash From Investing Activities -$5.917M -$1.528M
YoY Change 287.24% -210.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.00K 10.28M
YoY Change -99.46% -22940.0%
NET CHANGE
Cash From Operating Activities -5.201M 2.401M
Cash From Investing Activities -5.917M -1.528M
Cash From Financing Activities 55.00K 10.28M
Net Change In Cash -11.06M 11.15M
YoY Change -199.21% 787.11%
FREE CASH FLOW
Cash From Operating Activities -$5.201M $2.401M
Capital Expenditures $5.917M $3.884M
Free Cash Flow -$11.12M -$1.483M
YoY Change 649.7% -635.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
CY2021Q1 tkno Recognition Of Operating Lease Liabilities
RecognitionOfOperatingLeaseLiabilities
CY2021Q1 tkno Recognition Of Operating Right Of Use Lease Asset
RecognitionOfOperatingRightOfUseLeaseAsset
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
CY2022Q1 tkno Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
CY2022Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
CY2022Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
CY2022Q1 us-gaap Proceeds From Collection Of Longterm Loans To Related Parties
ProceedsFromCollectionOfLongtermLoansToRelatedParties
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001850902
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
CY2021Q1 tkno Non Cash Lease Expense
NonCashLeaseExpense
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 tkno Deferred Rent
DeferredRent
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40538
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
ALPHA TEKNOVA, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3368109
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2451 Bert Dr.
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hollister
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28042479
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11147000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4161000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9078000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5798000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4053000
CY2022Q1 us-gaap Gross Profit
GrossProfit
5349000
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95023
CY2022Q1 dei City Area Code
CityAreaCode
831
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
637-1100
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
TKNO
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
287000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
287000
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11192000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
5853000
CY2021Q1 us-gaap Gross Profit
GrossProfit
5025000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2013000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
700000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1597000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
705000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7295000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5843000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-828000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-13000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5856000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-820000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-359000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-165000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5497000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-655000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5497000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-648000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.20
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.18
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28030971
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3599232
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76455000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87518000
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
30000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
23000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2098000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12636000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7743000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2793000
CY2021Q4 us-gaap Inventory Net
InventoryNet
5394000
CY2022Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1188000
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1188000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1891000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
180000
CY2022Q1 us-gaap Assets
Assets
184084000
CY2021Q4 us-gaap Assets
Assets
166511000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3028000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2248000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7510000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5495000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5978000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4666000
CY2022Q1 us-gaap Inventory Net
InventoryNet
6426000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2438000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
91938000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
101204000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37059000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29810000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19661000
CY2022Q1 us-gaap Goodwill
Goodwill
16613000
CY2021Q4 us-gaap Goodwill
Goodwill
16613000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18417000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18704000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
396000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3153000
CY2022Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
253000
CY2021Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
273000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
11916000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
11870000
CY2021Q4 tkno Deferred Rent
DeferredRent
269000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17938000
CY2022Q1 us-gaap Liabilities
Liabilities
45536000
CY2021Q4 us-gaap Liabilities
Liabilities
23308000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28042479
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28042479
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28012017
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28012017
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
151583000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
150741000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13035000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7538000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
138548000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
143203000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
184084000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
166511000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
143203000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
787000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5497000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
138548000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
16767000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
183000
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-7000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-655000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
16288000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5497000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-655000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
7000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-88000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
-4000
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
-2000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
751000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
652000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
787000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
183000
CY2022Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-360000
CY2021Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-164000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
46000
CY2022Q1 tkno Non Cash Lease Expense
NonCashLeaseExpense
106000
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-10000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1319000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
400000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1028000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-295000
CY2021Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-177000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-547000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
348000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
237000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1283000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
762000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
847000
CY2022Q1 tkno Increase Decrease In Other Operating Assets And Liabilities
IncreaseDecreaseInOtherOperatingAssetsAndLiabilities
-236000
CY2021Q1 tkno Increase Decrease In Other Operating Assets And Liabilities
IncreaseDecreaseInOtherOperatingAssetsAndLiabilities
79000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5201000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2401000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5917000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3884000
CY2021Q1 us-gaap Proceeds From Collection Of Longterm Loans To Related Parties
ProceedsFromCollectionOfLongtermLoansToRelatedParties
529000
CY2021Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1132000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
695000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5917000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1528000
CY2021Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
11889000
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
153000
CY2021Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
1458000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10278000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11063000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11151000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87518000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3315000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76455000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14466000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
13000
CY2022Q1 tkno Capitalized Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities
CapitalizedPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
3884000
CY2021Q1 tkno Capitalized Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities
CapitalizedPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
673000
CY2021Q1 tkno Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
1425000
CY2022Q1 tkno Recognition Of Operating Lease Liabilities
RecognitionOfOperatingLeaseLiabilities
20237000
CY2022Q1 tkno Recognition Of Operating Right Of Use Lease Asset
RecognitionOfOperatingRightOfUseLeaseAsset
20507000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="i_notes" style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Nature of th</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">e Business</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Alpha Teknova, Inc. (referred to herein as the Company or Teknova), provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions, with catalog and custom, made-to-order products.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Teknova manufactures its products at its Hollister, California headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouses in Hollister, California and Mansfield, Massachusetts.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Teknova manufactures its products in Research Use Only (RUO) or Good Manufacturing Practice (GMP) categories, the latter of which refers to more stringent quality standards supported by additional levels of documentation, testing, and traceability. In 2017, Teknova achieved International Organization for Standardization (ISO) 13485:2016 certification, enabling the Company to manufacture products for use in diagnostic and therapeutic applications.</span></p>
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20300000
CY2022Q1 tkno Deferred Rent
DeferredRent
200000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
20500000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11147000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9078000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11147000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9078000
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3891000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3172000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
168000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
105000
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
2367000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2117000
CY2022Q1 us-gaap Inventory Net
InventoryNet
6426000
CY2021Q4 us-gaap Inventory Net
InventoryNet
5394000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14259000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13466000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2937000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2473000
CY2022Q1 tkno Property Plant And Equipment After Depreciation
PropertyPlantAndEquipmentAfterDepreciation
11322000
CY2021Q4 tkno Property Plant And Equipment After Depreciation
PropertyPlantAndEquipmentAfterDepreciation
10993000
CY2022Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
25737000
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
18817000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37059000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29810000
CY2022Q1 us-gaap Depreciation
Depreciation
500000
CY2021Q1 us-gaap Depreciation
Depreciation
400000
CY2022Q1 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
300000
CY2021Q1 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
CY2022Q1 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
700000
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.041
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2129000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2974000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2994000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2769000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2724000
CY2022Q1 tkno Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
10194000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23784000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3748000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
20036000
CY2022Q1 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
CY2021Q1 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
22099000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3682000
CY2022Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
18417000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
22099000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3395000
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
18704000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2022Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P4Y9M18D
CY2021Q3 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
5000000.0
CY2022Q1 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
5000000.0
CY2022Q1 tkno Final Borrowing Revenue Requirement
FinalBorrowingRevenueRequirement
37000000.0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.38
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
861000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1148000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1148000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1148000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1148000
CY2022Q1 tkno Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
45000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5498000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M26D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
24268000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2272000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2818000
CY2022Q1 tkno Accrued Liabilities Property Plant And Equipment Current
AccruedLiabilitiesPropertyPlantAndEquipmentCurrent
2607000
CY2021Q4 tkno Accrued Liabilities Property Plant And Equipment Current
AccruedLiabilitiesPropertyPlantAndEquipmentCurrent
1446000
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
1302000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
200000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1329000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1031000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7510000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5495000
CY2021Q1 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
5000000.0
CY2021Q1 us-gaap Line Of Credit Facility Description
LineOfCreditFacilityDescription
If any advance under the Term Loan is prepaid at any time, the prepayment fee is based on the amount being prepaid and an applicable percentage amount, such as 3%, 2%, or 1%, based on the date the prepayment is made after the closing date of the Term Loan.
CY2021Q1 tkno Term Loan
TermLoan
12000000.0
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
12000000.0
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
11900000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M17D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10952000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3222054
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.73
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
12000000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
12000000
CY2022Q1 tkno Debt Instrument Cumulative Accretion Of Exit Fee
DebtInstrumentCumulativeAccretionOfExitFee
120000
CY2021Q4 tkno Debt Instrument Cumulative Accretion Of Exit Fee
DebtInstrumentCumulativeAccretionOfExitFee
90000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
204000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
220000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
11916000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
11870000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4500000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1500000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12000000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2764112
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M8D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
45280000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
832650
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.07
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
30462
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
59564
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3506736
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.14
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M29D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28070000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
879411
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.38
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.3310
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.3616
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0201
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0048
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2022Q1 tkno Weighted Average Fair Value Of Common Stock
WeightedAverageFairValueOfCommonStock
15.07
CY2021Q1 tkno Weighted Average Fair Value Of Common Stock
WeightedAverageFairValueOfCommonStock
5.31
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.48
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.19
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
787000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
183000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12600000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M2D
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.061
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.201
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5497000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-655000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28030971
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3599232
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.20
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.18
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2844368
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11592908
CY2021Q1 us-gaap Notes Receivable Related Parties
NotesReceivableRelatedParties
500000

Files In Submission

Name View Source Status
0000950170-22-009650-index-headers.html Edgar Link pending
0000950170-22-009650-index.html Edgar Link pending
0000950170-22-009650.txt Edgar Link pending
0000950170-22-009650-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tkno-20220331.htm Edgar Link pending
tkno-20220331.xsd Edgar Link pending
tkno-20220331_cal.xml Edgar Link unprocessable
tkno-20220331_def.xml Edgar Link unprocessable
tkno-20220331_htm.xml Edgar Link completed
tkno-20220331_lab.xml Edgar Link unprocessable
tkno-20220331_pre.xml Edgar Link unprocessable
tkno-ex31_1.htm Edgar Link pending
tkno-ex31_2.htm Edgar Link pending
tkno-ex32_1.htm Edgar Link pending